Speeding Access to Precision Oncology Drugs: How Are We Doing With Biomarker-Driven Drug Approvals?

被引：1
|
作者：
Li, Tianhong [1 ,2 ]
机构：
[1] Univ Calif Davis, Comprehens Canc Ctr, Dept Internal Med, Div Hematol & Oncol, Davis, CA 95616 USA
[2] Univ Calif Davis, Comprehens Canc Ctr, Expt Therapeut Program, Davis, CA 95616 USA
来源：
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2020年 / 18卷 / 01期
关键词：
D O I：
10.6004/jnccn.2019.7523
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：113 / 114
页数：2
相关论文
共 17 条
  • [1] Liquid Biopsy: A Biomarker-Driven Tool towards Precision Oncology
    Yee, Nelson S.
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (08)
  • [2] Empowering effective biomarker-driven precision oncology: A call to action *
    Lawler, Mark
    Keeling, Peter
    Kholmanskikh, Olga
    Minnaard, Warnyta
    Moehlig-Zuttermeister, Heike
    Normanno, Nicola
    Philip, Reena
    Popp, Claudia
    Salgado, Roberto
    Santiago-Walker, Ademi E.
    Trullas, Ana
    van Waalwijk van Doorn-Khosrovani, Sahar B.
    Vart, Richard
    Vermeulen, Jessica
    Vitaloni, Marianna
    Verweij, Jaap
    EUROPEAN JOURNAL OF CANCER, 2024, 209
  • [3] The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics
    Barbieri, Christopher E.
    Chinnaiyan, Arul M.
    Lerner, Seth P.
    Swanton, Charles
    Rubin, Mark A.
    EUROPEAN UROLOGY, 2017, 71 (02) : 237 - 246
  • [4] Innovations in Precision Oncology: Biomarker-Driven Approaches for Enhanced Cancer Therapy
    Kargbo, Robert B.
    ACS MEDICINAL CHEMISTRY LETTERS, 2024, 15 (02): : 169 - 170
  • [5] UTILIZING A GENOMICS TAXONOMY: FACILITATING GENOMICS SAFETY IN THE BIOMARKER-DRIVEN ERA OF PRECISION ONCOLOGY
    Calzone, Kathleen
    Dickman, Erin
    Friend, Patricia
    ONCOLOGY NURSING FORUM, 2021, 48 (02)
  • [6] Biomarker-Driven Early Clinical Trials in Oncology A Paradigm Shift in Drug Development
    Tan, Daniel S. W.
    Thomas, George V.
    Garrett, Michelle D.
    Banerji, Udai
    de Bono, Johann S.
    Kaye, Stan B.
    Workman, Paul
    CANCER JOURNAL, 2009, 15 (05): : 406 - 420
  • [7] Biomarker-driven therapies for metastatic uveal melanoma: A prospective precision oncology feasibility study
    Leyvraz, Serge
    Konietschke, Frank
    Peuker, Caroline
    Schuette, Moritz
    Kessler, Thomas
    Ochsenreither, Sebastian
    Ditzhaus, Marc
    Spruenken, Erin D.
    Doerpholz, Gina
    Lamping, Mario
    Rieke, Damian T.
    Klinghammer, Konrad
    Burock, Susen
    Ulrich, Claas
    Poch, Gabriela
    Schaefer, Reinhold
    Klauschen, Frederick
    Joussen, Antonia
    Yaspo, Marie-Laure
    Keilholz, Ulrich
    EUROPEAN JOURNAL OF CANCER, 2022, 169 : 146 - 155
  • [8] Improving precision oncology through better designs and reporting of biomarker-driven randomized clinical trials
    LoRusso, Patricia M.
    Freidlin, Boris
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2023, 115 (02): : 122 - 124
  • [9] Leveraging innovative technology to generate drug response phenotypes for the advancement of biomarker-driven precision dosing
    Oni-Orisan, Akinyemi
    Srinivas, Nithya
    Mehta, Krina
    Das, Jesmin Lohy
    Nguyen, Thu T.
    Tison, Geoffrey H.
    Bauer, Scott R.
    Burian, Maria
    Funk, Ryan S.
    Graham, Richard A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 (06) : 1376 - 1376
  • [10] Leveraging innovative technology to generate drug response phenotypes for the advancement of biomarker-driven precision dosing
    Oni-Orisan, Akinyemi
    Srinivas, Nithya
    Mehta, Krina
    Das, Jesmin Lohy
    Nguyen, Thu T.
    Tison, Geoffrey H.
    Bauer, Scott R.
    Burian, Maria
    Funk, Ryan S.
    Graham, Richard A.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 14 (03): : 784 - 790
12